Could a transplant drug help fight brain cancer?
NCT ID NCT05236036
First seen Jan 15, 2026 · Last updated May 02, 2026 · Updated 15 times
Summary
This early-phase trial tests the safety and best dose of mycophenolate mofetil, a drug usually used to prevent organ rejection, when added to standard chemotherapy and radiation for glioblastoma. About 60 adults with newly diagnosed or recurrent glioblastoma will take part. The goal is to see if this combination can make chemotherapy work better and help control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Northwestern Lake Forest Hospital
Lake Forest, Illinois, 60045, United States
-
Northwestern Medicine Warrenville
Warrenville, Illinois, 60555, United States
-
Northwestern University
Chicago, Illinois, 60611, United States
Conditions
Explore the condition pages connected to this study.